Nature Communications (Nov 2022)
MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling
- Dario Zimmerli,
- Chiara S. Brambillasca,
- Francien Talens,
- Jinhyuk Bhin,
- Renske Linstra,
- Lou Romanens,
- Arkajyoti Bhattacharya,
- Stacey E. P. Joosten,
- Ana Moises Da Silva,
- Nuno Padrao,
- Max D. Wellenstein,
- Kelly Kersten,
- Mart de Boo,
- Maurits Roorda,
- Linda Henneman,
- Roebi de Bruijn,
- Stefano Annunziato,
- Eline van der Burg,
- Anne Paulien Drenth,
- Catrin Lutz,
- Theresa Endres,
- Marieke van de Ven,
- Martin Eilers,
- Lodewyk Wessels,
- Karin E. de Visser,
- Wilbert Zwart,
- Rudolf S. N. Fehrmann,
- Marcel A. T. M. van Vugt,
- Jos Jonkers
Affiliations
- Dario Zimmerli
- Division of Molecular Pathology, The Netherlands Cancer Institute
- Chiara S. Brambillasca
- Division of Molecular Pathology, The Netherlands Cancer Institute
- Francien Talens
- Department of Medical Oncology, University Medical Center Groningen, University of Groningen
- Jinhyuk Bhin
- Division of Molecular Pathology, The Netherlands Cancer Institute
- Renske Linstra
- Department of Medical Oncology, University Medical Center Groningen, University of Groningen
- Lou Romanens
- Division of Molecular Pathology, The Netherlands Cancer Institute
- Arkajyoti Bhattacharya
- Department of Medical Oncology, University Medical Center Groningen, University of Groningen
- Stacey E. P. Joosten
- Oncode Institute
- Ana Moises Da Silva
- Division of Molecular Pathology, The Netherlands Cancer Institute
- Nuno Padrao
- Oncode Institute
- Max D. Wellenstein
- Oncode Institute
- Kelly Kersten
- Division of Oncogenomics, The Netherlands Cancer Institute
- Mart de Boo
- Division of Molecular Pathology, The Netherlands Cancer Institute
- Maurits Roorda
- Department of Medical Oncology, University Medical Center Groningen, University of Groningen
- Linda Henneman
- Transgenic Core Facility, Mouse Clinic for Cancer and Aging (MCCA), The Netherlands Cancer Institute
- Roebi de Bruijn
- Division of Molecular Pathology, The Netherlands Cancer Institute
- Stefano Annunziato
- Division of Molecular Pathology, The Netherlands Cancer Institute
- Eline van der Burg
- Division of Molecular Pathology, The Netherlands Cancer Institute
- Anne Paulien Drenth
- Division of Molecular Pathology, The Netherlands Cancer Institute
- Catrin Lutz
- Division of Molecular Pathology, The Netherlands Cancer Institute
- Theresa Endres
- Theodor Boveri Institute, Department of Biochemistry and Molecular Biology, Biocenter, University of Würzburg, Am Hubland
- Marieke van de Ven
- Preclinical Intervention Unit, Mouse Clinic for Cancer and Aging (MCCA), The Netherlands Cancer Institute
- Martin Eilers
- Theodor Boveri Institute, Department of Biochemistry and Molecular Biology, Biocenter, University of Würzburg, Am Hubland
- Lodewyk Wessels
- Oncode Institute
- Karin E. de Visser
- Oncode Institute
- Wilbert Zwart
- Oncode Institute
- Rudolf S. N. Fehrmann
- Department of Medical Oncology, University Medical Center Groningen, University of Groningen
- Marcel A. T. M. van Vugt
- Department of Medical Oncology, University Medical Center Groningen, University of Groningen
- Jos Jonkers
- Division of Molecular Pathology, The Netherlands Cancer Institute
- DOI
- https://doi.org/10.1038/s41467-022-34000-6
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 18
Abstract
Tripe-negative breast cancers poorly respond to immune checkpoint inhibition therapy, due to their immune-hostile tumour microenvironment. Authors here show that the oncogene MYC plays a pivotal role in suppressing anti-tumour immunity via directly regulating the transcription of interferon signalling genes.
